NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

VKTX

Viking Therapeutics Inc

Jul 03 • 04:00PM ET

28.19

Dollar change +0.47
Percentage change 1.70	%

Healthcare • Biotechnology • USA • NASD

Peers: MDGL AKRO GLMD AKBA PRTG ARDX BOLD TVRD EYPT FGEN

| Held by: VTI VB XBI VXF VBK SCHA IWR VHT IWD LABU

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.15	Insider Own	2.96%	Shs Outstand	112.29M	Perf Week	0.07%
Market Cap	3.17B	Forward P/E	-	EPS next Y	-2.57	Insider Trans	-9.11%	Shs Float	108.99M	Perf Month	5.94%
Enterprise Value	2.32B	PEG	-	EPS next Q	-0.45	Inst Own	69.32%	Short Float	26.13%	Perf Quarter	9.77%
Income	-128.24M	P/S	-	EPS this Y	-86.96%	Inst Trans	-5.22%	Short Ratio	7.26	Perf Half Y	-29.12%
Sales	0.00M	P/B	3.74	EPS next Y	-35.97%	ROA	-13.98%	Short Interest	28.47M	Perf YTD	-29.95%
Book/sh	7.54	P/C	3.72	EPS next 5Y	-	ROE	-14.40%	52W High	81.73 -65.51%	Perf Year	-49.04%
Cash/sh	7.58	P/FCF	-	EPS past 3/5Y	-12.29% -23.00%	ROIC	-15.13%	52W Low	18.92 49.00%	Perf 3Y	940.22%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.25% 6.11%	Perf 5Y	272.88%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-23.84%	Oper. Margin	-	ATR (14)	1.63	Perf 10Y	297.60%
Dividend Ex-Date	-	Quick Ratio	44.25	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	55.39	Recom	1.21
Dividend Gr. 3/5Y	- -	Current Ratio	44.25	EPS Q/Q	-54.01%	SMA20	3.73%	Beta	0.65	Target Price	90.26
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	3.20%	Rel Volume	0.61	Prev Close	27.72
Employees	36	LT Debt/Eq	0.00	Earnings	Apr 23 AMC	SMA200	-29.27%	Avg Volume	3.92M	Price	28.19
IPO	Apr 29, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-25.00% -	Trades		Volume	2,383,461	Change	1.70%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$104
Apr-08-25	Initiated	Goldman	Neutral	$30
Feb-13-25	Initiated	Scotiabank	Sector Outperform	$102
Feb-07-25	Initiated	Citigroup	Neutral	$38
Dec-02-24	Initiated	Piper Sandler	Overweight
Nov-22-24	Initiated	B. Riley Securities	Buy	$109
Nov-04-24	Reiterated	H.C. Wainwright	Buy	$90 → $102
Sep-11-24	Initiated	JP Morgan	Overweight	$80
Jun-27-24	Initiated	Morgan Stanley	Overweight	$105
May-16-24	Upgrade	Raymond James	Outperform → Strong Buy	$115 → $116
Mar-26-24	Reiterated	Oppenheimer	Outperform	$116 → $138
Mar-07-24	Initiated	Jefferies	Buy	$110
Feb-28-24	Reiterated	Oppenheimer	Outperform	$46 → $116
May-31-23	Resumed	ROTH MKM	Buy	$32
Mar-28-23	Reiterated	Maxim Group	Buy	$15 → $25
Mar-17-23	Initiated	Stifel	Buy	$22
Jul-29-21	Resumed	BTIG Research	Buy	$20
May-25-21	Downgrade	Raymond James	Strong Buy → Outperform	$27 → $12
Jun-05-20	Initiated	BMO Capital Markets	Outperform	$14
May-05-20	Initiated	Chardan Capital Markets	Buy	$15

Show Previous Ratings

Jul-04-25 04:30AM	Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity (Motley Fool)
01:01AM	Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns. (Barrons.com)
Jul-03-25 05:45PM	Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts (Zacks)
07:00AM	2 Beaten-Down Stocks With Massive Upside Potential (Motley Fool)
Jul-02-25 09:30AM	Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
06:30AM	Loading…
06:30AM	10 Incredible Growth Stocks Poised for Long-Term Gains (Motley Fool)
Jul-01-25 07:15AM	Got $200? 2 Biotech Stocks to Buy and Hold Forever (Motley Fool)
Jun-30-25 04:05PM	Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? (Investor's Business Daily)
Jun-29-25 08:36AM	3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking (MarketBeat)
Jun-27-25 05:45PM	Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note (Zacks) -5.86%
11:10AM	NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now? (Zacks)
10:10AM	Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed? (Zacks)
Jun-26-25 01:59PM	Why This Weight Loss Drug Company's Stock Surged Today (Motley Fool)
11:38AM	Viking commences Phase III clinical programme of VK2735 for obesity (Clinical Trials Arena)
11:12AM	VKTX Initiates Phase 3 Study on Obesity Candidate VK2735 (Zacks)
09:43AM	Loading…
09:43AM	Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth? (Zacks)
05:15AM	3 Growth Stocks I'm Loading Up On (Motley Fool)
Jun-25-25 02:09PM	Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity (Investor's Business Daily)
07:03AM	Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 (PR Newswire)
Jun-24-25 11:25AM	Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers? (Zacks) +8.41%
07:10AM	My 5 Favorite Dirt Cheap Stocks to Buy Right Now (Motley Fool)
Jun-21-25 06:10PM	2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts (Motley Fool)
Jun-20-25 05:45PM	Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know (Zacks)
Jun-18-25 10:52AM	Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space? (Zacks)
09:53AM	Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. (Motley Fool)
Jun-16-25 12:35PM	Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do? (Zacks)
09:30AM	Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet (Zacks)
07:30AM	Are These 2 High-Flying Growth Stocks Still Worth Buying After Recent Pullbacks? (Motley Fool)
Jun-13-25 10:41AM	Lilly Moves Past 50-Day Average: Should You Buy the Stock Now? (Zacks) -8.75%
Jun-12-25 06:33PM	Viking Therapeutics (VKTX) Rises on Expected Developments (Insider Monkey)
05:45PM	Loading…
05:45PM	Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
Jun-11-25 09:38AM	Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space? (Zacks)
Jun-09-25 10:27AM	Was Jim Cramer Right to Favor Another Stock Over Viking Therapeutics (VKTX)? (Insider Monkey)
Jun-08-25 05:55AM	1 Stock Down 34% This Year to Buy and Hold (Motley Fool)
Jun-06-25 12:38PM	Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer? (Zacks)
Jun-03-25 05:45PM	Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know (Zacks)
Jun-02-25 06:45AM	Could Viking Therapeutics Become the Next Eli Lilly? (Motley Fool)
06:15AM	3 Best Growth Stocks to Buy in June (Motley Fool)
May-30-25 09:30AM	Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? (Zacks)
May-27-25 12:38PM	Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside? (Zacks)
May-22-25 11:05AM	Better Weight Loss Stock: Amgen or Viking Therapeutics? (Motley Fool)
May-19-25 10:15AM	Novo Nordisk Shares Dip 3% on Sudden CEO Transition Announcement (Zacks)
May-16-25 05:20PM	Why Viking Therapeutics Stock Bumped 3% Higher Today (Motley Fool)
11:00AM	Novo Nordisk Sheds 3% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price (Investor's Business Daily)
09:07AM	Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do? (Zacks)
May-14-25 08:51AM	Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock? (Zacks)
May-13-25 07:08PM	Why Weight-Loss Developer Stocks Tumbled on Tuesday (Motley Fool)
09:45AM	2 Monster Stocks in the Making to Buy Now and Hold for 10 Years (Motley Fool)
May-11-25 11:15AM	3 Monster Stocks in the Making (Motley Fool)
May-06-25 04:33AM	Why Viking Therapeutics Stock Surged Nearly 20% Higher in April (Motley Fool) -8.41%
May-03-25 09:30AM	Eli Lilly's Meltdown Triggers Near Doubling Upside Potential - Reiterate Buy (Seeking Alpha)
May-02-25 05:48PM	Why Viking Therapeutics Stock Was Victorious This Week (Motley Fool)
11:55AM	Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday (Motley Fool)
06:45AM	Is Novo Nordisk Stock a Buy? (Motley Fool)
04:20AM	Where Will Viking Therapeutics Be in 3 Years? (Motley Fool)
May-01-25 12:34PM	3 Market Predictions For May (Seeking Alpha)
05:47AM	1 Beaten-Down Stock to Buy and Hold for 10 Years (Motley Fool)
Apr-30-25 04:51AM	Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? (Motley Fool)
04:51AM	Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? (Motley Fool)
03:15AM	Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain (Motley Fool)
Apr-29-25 12:24PM	Why Viking Therapeutics Stock Popped Again Today (Motley Fool) +7.71%
10:20AM	Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock? (Zacks)
Apr-28-25 11:41AM	Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised) (Zacks)
11:06AM	Why Viking Therapeutics Stock Popped Today (Motley Fool)
07:45AM	Is Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings? (Zacks)
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Apr-25-25 08:00AM	Viking Therapeutics Stock May Struggle After As-Expected Report (MarketBeat)
Apr-24-25 11:18AM	Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock? (Zacks)
09:16AM	Q1 2025 Viking Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
08:58AM	Viking Therapeutics: Q1 Earnings Overview - Hard To Understand Wall Street's Pessimism (Seeking Alpha)
06:31AM	Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips (Zacks)
03:06AM	Viking Therapeutics Inc (VKTX) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising ... (GuruFocus.com)
Apr-23-25 08:48PM	Viking Therapeutics, Inc. (VKTX): Among Takeover Rumors Hedge Funds Are Buying (Insider Monkey)
07:46PM	Viking Therapeutics, Inc. (VKTX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
04:05PM	Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Apr-22-25 09:30AM	Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? (Zacks) +7.42%
Apr-21-25 08:37AM	LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study (Zacks)
07:36AM	Viking Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-18-25 11:55AM	H.C. Wainwright still expects Viking to differentiate after Lilly data (TipRanks)
11:25AM	Eli Lilly jumps as results from weight-loss pill study rival competitors (TipRanks)
10:26AM	JPMorgan says Lilly data highly favorable for Structure Therapeutics (TipRanks)
Apr-17-25 05:50PM	Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
04:10PM	Eli Lilly Rockets 14% After Solidifying Its Lead For A Weight-Loss Pill (Investor's Business Daily)
12:46PM	Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide (Motley Fool)
11:36AM	Wall Street Lunch: Obesity Pill Progress (Seeking Alpha)
10:28AM	89bio: Primary Asset Targeting 2 Potential Indications And Is In Late-Stage Development (Seeking Alpha)
10:00AM	2 Stocks Down by 25% or More This Year to Buy and Hold (Motley Fool)
09:30AM	Viking Therapeutics: A Lot More Compelling After The Meltdown - Initiating Cautious Buy (Rating Upgrade) (Seeking Alpha)
08:34AM	Eli Lilly Stock Rockets On Weight-Loss Pill Progress (Investor's Business Daily)
Apr-16-25 04:05PM	Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025 (PR Newswire)
10:33AM	Viking Therapeutics Stock Pops But Struggles to Hold Gains (MarketBeat)
07:05AM	Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip? (Zacks)
Apr-15-25 04:21PM	Viking Therapeutics: Trading The Volatility Of The Weight Loss Drug Market (Seeking Alpha) -5.94%
02:37PM	Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes (Seeking Alpha)
12:57PM	Pfizer Halts Obesity Pill Development Amid Safety Concerns (Zacks)
10:35AM	Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill (TipRanks)
10:15AM	Down 71%, Should You Buy the Dip on Viking Therapeutics Stock? (Motley Fool)
10:00AM	NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback (Zacks)
12:40AM	Why Viking Therapeutics, Inc. (VKTX) Skyrocketed On Monday? (Insider Monkey)
Apr-14-25 11:12AM	Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today (Motley Fool) +10.58%

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lian Brian	President & CEO	Jul 03 '25	Sale	27.80	26,889	747,633	2,388,014	Jul 03 03:31 PM
ZANTE GREG	Chief Financial Officer	Jul 03 '25	Sale	27.76	4,266	118,428	168,660	Jul 03 03:31 PM
Mancini Marianna	Chief Operating Officer	Jul 03 '25	Sale	27.77	4,266	118,473	377,535	Jul 03 03:30 PM
GREG ZANTE	Officer	Jul 03 '25	Proposed Sale	27.76	4,266	118,428		Jul 03 01:07 PM
MARIANNA MANCINI	Officer	Jul 03 '25	Proposed Sale	27.77	4,266	118,473		Jul 03 01:05 PM
BRIAN LIAN	Officer	Jul 03 '25	Proposed Sale	27.80	26,889	747,633		Jul 03 01:01 PM
FOEHR MATTHEW W	Director	Apr 11 '25	Option Exercise	8.00	20,786	166,288	132,036	Apr 14 07:26 PM
Rouan Sarah Kathryn	Director	Mar 31 '25	Buy	24.15	1,240	29,943	1,240	Apr 02 06:29 PM
Lian Brian	President & CEO	Jan 06 '25	Sale	42.75	194,490	8,313,601	2,366,570	Jan 06 08:16 PM
Mancini Marianna	Chief Operating Officer	Jan 06 '25	Sale	42.75	54,215	2,317,599	374,134	Jan 06 08:15 PM
ZANTE GREG	Chief Financial Officer	Jan 06 '25	Sale	42.75	50,309	2,150,595	165,259	Jan 06 08:14 PM
GREG ZANTE	Officer	Jan 06 '25	Proposed Sale	42.75	50,309	2,150,594		Jan 06 05:32 PM
MARIANNA MANCINI	Officer	Jan 06 '25	Proposed Sale	42.75	54,215	2,317,599		Jan 06 05:25 PM
BRIAN LIAN	Officer	Jan 06 '25	Proposed Sale	42.75	194,490	8,313,611		Jan 06 05:16 PM
MACARTNEY LAWSON	Director	Nov 08 '24	Option Exercise	5.80	2,000	11,600	49,965	Nov 08 06:22 PM
MACARTNEY LAWSON	Director	Nov 08 '24	Sale	68.67	2,000	137,333	47,965	Nov 08 06:22 PM
LAWSON MACARTNEY	Director	Nov 08 '24	Proposed Sale	68.67	2,000	137,333		Nov 08 06:13 PM
ZANTE GREG	Chief Financial Officer	Oct 28 '24	Option Exercise	7.49	94,001	704,282	281,053	Oct 28 09:48 PM
ZANTE GREG	Chief Financial Officer	Oct 28 '24	Sale	76.61	131,687	10,089,164	149,366	Oct 28 09:48 PM
GREG ZANTE	Officer	Oct 28 '24	Proposed Sale	78.03	131,687	10,275,537		Oct 28 04:37 PM
Rouan Sarah Kathryn	Director	Oct 25 '24	Option Exercise	4.88	11,000	53,680	11,000	Oct 25 07:28 PM
Rouan Sarah Kathryn	Director	Oct 25 '24	Sale	80.89	11,000	889,790	0	Oct 25 07:28 PM
SINGLETON J MATTHEW	Director	Oct 25 '24	Option Exercise	4.48	16,000	71,680	25,500	Oct 25 07:27 PM
SINGLETON J MATTHEW	Director	Oct 25 '24	Sale	79.50	16,000	1,272,000	9,500	Oct 25 07:27 PM
Rouan Sarah Kathryn	Director	Oct 25 '24	Proposed Sale	80.86	11,000	889,430		Oct 25 04:10 PM
SINGLETON J MATTHEW	Director	Oct 25 '24	Proposed Sale	79.47	16,000	1,271,479		Oct 25 04:01 PM
SINGLETON J MATTHEW	Director	Sep 20 '24	Option Exercise	1.19	10,300	12,257	19,800	Sep 20 09:21 PM
SINGLETON J MATTHEW	Director	Sep 20 '24	Sale	69.50	10,300	715,850	9,500	Sep 20 09:21 PM
Lian Brian	President & CEO	Sep 20 '24	Option Exercise	7.77	166,130	1,290,830	2,521,057	Sep 20 09:20 PM
Lian Brian	President & CEO	Sep 20 '24	Sale	70.83	216,130	15,308,553	2,304,927	Sep 20 09:20 PM
Lian Brian	Officer	Sep 20 '24	Proposed Sale	18.41	216,130	3,978,372		Sep 20 04:29 PM
SINGLETON J MATTHEW	Director	Sep 20 '24	Proposed Sale	69.50	10,300	715,850		Sep 20 04:13 PM
Lian Brian	President & CEO	Aug 21 '24	Option Exercise	7.77	1,000	7,770	2,355,927	Aug 22 07:23 PM
Lian Brian	President & CEO	Aug 21 '24	Sale	69.90	1,000	69,900	2,354,927	Aug 22 07:23 PM
SINGLETON J MATTHEW	Director	Aug 21 '24	Option Exercise	1.19	5,700	6,783	15,200	Aug 22 07:23 PM
SINGLETON J MATTHEW	Director	Aug 21 '24	Sale	69.72	5,700	397,430	9,500	Aug 22 07:23 PM
Lian Brian	Officer	Aug 21 '24	Proposed Sale	69.90	1,000	69,900		Aug 21 04:30 PM
SINGLETON J MATTHEW	Director	Aug 21 '24	Proposed Sale	69.72	5,700	397,404		Aug 21 04:18 PM
Lian Brian	President & CEO	Aug 19 '24	Option Exercise	7.77	112,870	877,000	2,467,797	Aug 19 08:13 PM
Lian Brian	President & CEO	Aug 19 '24	Sale	65.80	112,870	7,426,508	2,354,927	Aug 19 08:13 PM
SINGLETON J MATTHEW	Director	Aug 19 '24	Option Exercise	3.33	16,000	53,280	25,500	Aug 19 08:11 PM
SINGLETON J MATTHEW	Director	Aug 19 '24	Sale	62.22	16,000	995,453	9,500	Aug 19 08:11 PM
Lian Brian	Officer	Aug 19 '24	Proposed Sale	65.79	112,870	7,425,717		Aug 19 08:00 PM
SINGLETON J MATTHEW	Director	Aug 19 '24	Proposed Sale	62.21	16,000	995,360		Aug 19 07:47 PM
SINGLETON J MATTHEW	Director	Aug 14 '24	Option Exercise	8.00	20,786	166,288	30,286	Aug 14 08:03 PM
SINGLETON J MATTHEW	Director	Aug 14 '24	Sale	57.53	20,786	1,195,736	9,500	Aug 14 08:03 PM
SINGLETON J MATTHEW	Director	Aug 14 '24	Proposed Sale	57.53	20,786	1,195,735		Aug 14 04:38 PM
ZANTE GREG	Chief Financial Officer	Jul 30 '24	Sale	57.15	16,136	922,212	187,052	Jul 31 04:05 PM
Lian Brian	President & CEO	Jul 30 '24	Sale	57.58	115,859	6,670,604	2,354,927	Jul 31 04:05 PM
Mancini Marianna	Chief Operating Officer	Jul 30 '24	Sale	57.13	18,026	1,029,912	362,149	Jul 31 04:05 PM
GREG ZANTE	Officer	Jul 30 '24	Proposed Sale	57.15	16,136	922,232		Jul 30 05:58 PM
MARIANNA MANCINI	Officer	Jul 30 '24	Proposed Sale	57.13	18,026	1,029,888		Jul 30 05:56 PM
BRIAN LIAN	Officer	Jul 30 '24	Proposed Sale	57.58	115,859	6,671,057		Jul 30 05:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VKTX

Viking Therapeutics Inc

Upgrade your FINVIZ experience